The latest price target for ImmunoPrecise Antibodies (NASDAQ:IPA) was reported by HC Wainwright & Co. on December 11, 2024. The analyst firm set a price target for $7.00 expecting IPA to rise to within 12 months (a possible 1608.15% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for ImmunoPrecise Antibodies (NASDAQ:IPA) was provided by HC Wainwright & Co., and ImmunoPrecise Antibodies maintained their buy rating.

There is no last upgrade for ImmunoPrecise Antibodies

There is no last downgrade for ImmunoPrecise Antibodies.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunoPrecise Antibodies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunoPrecise Antibodies was filed on December 11, 2024 so you should expect the next rating to be made available sometime around December 11, 2025.

While ratings are subjective and will change, the latest ImmunoPrecise Antibodies (IPA) rating was a maintained with a price target of $9.00 to $7.00. The current price ImmunoPrecise Antibodies (IPA) is trading at is $0.41, which is out of the analyst’s predicted range.